CAS 936623-90-4 Lcz696 Sacubitril Valsartan

China CAS 936623-90-4 Lcz696 Sacubitril Valsartan, Find details about China Sacubitril Valsartan, Lcz696 from CAS 936623-90-4 Lcz696 Sacubitril Valsartan

Basic Info.

Model NO.

TY-02ALI

CAS No.

936623-90-4

Appearance

White Powder

Einecs

616-396-9

Assay

99%

Shelf

2 Years

Trademark

tongyon

Transport Package

25kg/Drum 1kg, 10kg, 100kg, 200kg

Specification

25kg/drum

Origin

China

Model NO.

TY-02ALI

CAS No.

936623-90-4

Appearance

White Powder

Einecs

616-396-9

Assay

99%

Shelf

2 Years

Trademark

tongyon

Transport Package

25kg/Drum 1kg, 10kg, 100kg, 200kg

Specification

25kg/drum

Origin

China

Product Desciption

CAS 936623-90-4 Lcz696 Sacubitril Valsartan

Product name	LCZ696
CAS	936623-90-4
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Product Name:LCZ696
CAS:936623-90-4
MF:C48H58N6O8
MW:847.00952
EINECS:000-000-0
Mol File:936623-90-4.mol

CAS 936623-90-4 Lcz696 Sacubitril Valsartan

LCZ696 a drug developed by Novartis Pharmaceutical of the United States for the treatment of heart failure. Heart failure is a life-threatening disease. The patient's heart cannot pump enough blood to supply the body, and appear the symptoms of dyspnea, fatigue and fluid retention slowly, then gradually increased, significantly affect the quality of life.
LCZ696 is a dual-acting angiotensin-receptor enkephalinase inhibitor that has a unique mechanism that is thought to reduce the strain of failing hearts. LCZ696 can enhance the body's natural defense against heart failure, as well as increase the level of natriuretic peptides and other endogenous vasoactive peptides, and inhibit the renin-angiotensin-aldosterone system (RAAS). LCZ696 has combined with Novartis's Hypertension Medication (Diovan, generic name: valsartan) and the experimental drug AHU-377. AHU377 blocks the mechanism of the two peptides responsible for lowering blood pressure. Diovan improves vasodilatation and stimulates the body to excrete sodium and water.
The safety threshold of cardiovascular drugs is extremely high, and LCZ696 even shows a higher safety than conventional drugs. Previously, Novartis vigorously develop the cardiovascular drug- serelaxi, while because of security issues, both the FDA and the European Union did not grant this drug. This is undoubtedly a heavy blow to Novartis. However, the success of LCZ696 will pay back Novartis a big era in the cardiovascular field.

GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.

CAS 936623-90-4 Lcz696 Sacubitril Valsartan